Cargando…

The R2-ISS in a Multicenter Cohort of Chinese Patients With Newly Diagnosed Multiple Myeloma

Detalles Bibliográficos
Autores principales:	Yang, Peiyu, Zhou, Fan, Dong, Yujun, Gao, Guangxun, Xue, Hua, Liang, Xinyue, Yu, Shanshan, Xu, Weiling, Ma, Yanping, Qin, Xiaoqi, Li, Mengyao, Dai, Yun, Jin, Fengyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043562/ https://www.ncbi.nlm.nih.gov/pubmed/36999007 http://dx.doi.org/10.1097/HS9.0000000000000857

Ejemplares similares

The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma
por: Yang, Peiyu, et al.
Publicado: (2022)

High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
por: Hagen, Patrick, et al.
Publicado: (2022)

Comparative survival analysis using the International Stratification Score (ISS) in newly-diagnosed multiple myeloma in the Uruguayan population
por: Garrido, David Israel, et al.
Publicado: (2021)

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma
por: Liu, Shanshan, et al.
Publicado: (2023)

Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and (18)F-FDG PET/CT
por: Cho, Hee Jeong, et al.
Publicado: (2021)

Prognostic value of the Second Revision of the International Staging System (R2-ISS) in a real-world cohort of patients with newly-diagnosed multiple myeloma
por: Yan, Wenqiang, et al.
Publicado: (2023)

Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis
por: Lu, J, et al.
Publicado: (2014)

P817: VALIDATION OF THE SECOND REVISED INTERNATIONAL STAGING SYSTEM (R2-ISS) IN A LARGE POPULATION-BASED, NATIONWIDE COHORT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Brieghel, Christian, et al.
Publicado: (2023)

AMS - ISS
por: Vanden Broeck, Renilde
Publicado: (2019)

Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients
por: Hu, Ying, et al.
Publicado: (2019)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

CALET docked on the ISS
por: Antonella Del Rosso
Publicado: (2015)

P02: PROGNOSTIC STRATIFICATION OF STANDARD RISK MULTIPLE MYELOMA DEFINED BY REVISED ISS
por: Barilà, G, et al.
Publicado: (2022)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan
por: Suzuki, Tomotaka, et al.
Publicado: (2022)

Performance of the ISS-CREAM Calorimeter
por: Picot-Clémente, Nicolas, et al.
Publicado: (2017)

The CALET Instrument for Experiment on the ISS
por: Torii, S
Publicado: (2005)

The ISOLDE Solenoidal Spectrometer (ISS)
por: Ordan, Julien Marius
Publicado: (2022)

Medipix in space on-board the ISS
por: Pinsky, Lawrence S., et al.
Publicado: (2014)

Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities
por: Jia, Shuangshuang, et al.
Publicado: (2022)

Severe renal impairment as an adverse prognostic factor for survival in newly diagnosed multiple myeloma patients
por: Chen, Xuduan, et al.
Publicado: (2020)

Clinical significance of granule‐containing myeloma cells in patients with newly diagnosed multiple myeloma
por: Suzuki, Kazuhito, et al.
Publicado: (2016)

Competing endogenous RNA network in newly diagnosed multiple myeloma by genetic microarray
por: He, Yu-Qin, et al.
Publicado: (2020)

Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
por: Hsu, Pei, et al.
Publicado: (2015)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
por: Hassan Zafar, Mir Sadaqat, et al.
Publicado: (2018)

Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma
por: Landgren, Ola, et al.
Publicado: (2019)

Unexpected Heterogeneity of Newly Diagnosed Multiple Myeloma Patients with Plasmacytomas
por: Stork, Martin, et al.
Publicado: (2022)

Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation
por: Ma, Kewa, et al.
Publicado: (2021)

Two Graphical User Interfaces for ISS
por: Baader, Edith Franziska
Publicado: (2018)

First Swede in space will visit the ISS
Publicado: (2002)

ISS education programme: space for learning
por: European Space Agency. Noordwijk. ISS Education and Strategy Office
Publicado: (2003)

Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
por: Liu, Xiao, et al.
Publicado: (2022)

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study
por: Fan, Huishou, et al.
Publicado: (2023)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e8qlfdphiseua39drqqojlofnv